Rein Therapeutics, Inc. · NASDAQ:RNTX
Voss Capital, LP reported a 6.60% stake in Rein Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Jul 14, 2026
Voss Capital, LP reported a 6.60% stake in Rein Therapeutics, Inc., 5,656,957 shares, as a passive investor on Jun 30, 2026. Filed Jul 14, 2026 (Schedule 13G/A).
- Stake
- 6.60%
- Shares
- 5,656,957
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Voss Value Master Fund, LP | 1.20% | 1,000,000 |
| Voss Value-Oriented Special Situations Fund, LP | 0.60% | 500,000 |
| Voss Advisors GP, LLC | 1.80% | 1,500,000 |
| Voss Capital, LP | 6.60% | 5,656,957 |
| Cocke Travis W. | 6.60% | 5,656,957 |
Source
Related
- Rein Therapeutics, Inc.
- Voss Capital, LP
- Rein Therapeutics, Inc. shareholders
- Schedule 13G/A · Voss Capital, LP · Feb 13, 2026
- Schedule 13G/A · Voss Capital, LP · Sep 26, 2025
- Schedule 13G · Voss Capital, LP · May 14, 2025
- Schedule 13G/A · Lynwood Capital Management Inc. · Aug 14, 2026
- Schedule 13G · ADAR1 Capital Management, LLC · Aug 14, 2026
- Schedule 13G/A · Laurence W. Lytton · Aug 13, 2026
- Form 4 · Von Rickenbach Josef H · May 28, 2026
- Form 4 · Windsor James Brian · May 13, 2026